

For current reference


Human Toxicity...
 Propionyl Chloride. $\text{CH}_3\text{CH}_2\text{COCl}$, mol. wt. 92.53.
 C 38.94%, H 5.45%, O 17.29%, Cl 38.32%.
 acid 80.06%.
 Liquid, pungent odor. d_4^{20} 1.065; m. -9° ; b. 80° ;
 n_D^{20} 1.4051. Vigorously decomposed and dissolved by
 ether of alcohol.

Propionyl Erythromycin Ester Lauryl Sulphate
 A new antibiotic development

Propiophenone. 1-phenyl-1 propanone; ethyl phenyl
 ketone; propionylbenzene; phenyl ethyl ketone. $\text{C}_9\text{H}_{10}\text{O}$
 H₁₀O; mol. wt. 134.17. C 80.56%, H 7.51%, O 11.93%.
 Prep'd. from propionyl chloride and benzene in the presence of
 anhydrous aluminum chloride:
 Read, *J. Am. Chem. Soc.* 44, 1751 (1922). Numerous other syn-
 theses.

traction with alcohol...
 from the alcohol...
 yielding propolis...
 ether. Propolis...
 to contain 10%...
 Proposote...
 about 50% creo...
 Straw-colore...
 slightly bitter...
 in water or ac...
 posed by alk...
 Med. Use

Propoxyrain
 amino-2-p...
 poxybenz...
 ride; 2'-...
 hydroch...
 hydroch...
 HCl; r



'ILOSONE'

TRADE MARK

Too recent to be in the books of reference yet, but its virtues will ensure wide and early recognition as an outstanding antibiotic development.

'Ilosone' possesses a spectrum effective against most of the common pathogens. It gives quicker, higher and more prolonged activity than any other member of the erythromycin group. Moreover, 'Ilosone' is extraordinarily safe.

PRESENTATION

'PULVULES' 'ILOSONE'
 125mg.
 250mg.

SUSPENSION 'ILOSONE'
 125mg. per 5cc. when prepared.

DOSAGE

250mg. every six hours (1 Gm. daily), doubled in serious infections.

Half to two teaspoonfuls or more.

A *Lilly* Discovery

ELI LILLY AND COMPANY LIMITED · BASINGSTOKE · ENGLAND

JOURNAL OF MENTAL SCIENCE

CONTENTS FOR JANUARY, 1961

Original Articles—	PAGE
The History of Mental Nursing; by <i>Alexander Walk, M.D., D.P.M.</i>	1
A Study of Alcoholism as an Occupational Hazard of Merchant Seamen; by <i>Harry K. Rose, L.R.C.P.&S.(Ed.), D.P.H., D.P.M., and M. M. Glatt, M.D., D.P.M.</i>	18
Drugs—A Tool for Research in Psychiatry; by <i>John C. Saunders, M.D.</i>	31
Moustaches; by <i>G. R. Peberdy, M.D.</i>	40
A Note on "Distance Constancy in Schizophrenic Patients"; by <i>E. E. Rump, B.Sc.</i>	48
Verbal Abstraction in Psychiatric Illness; by <i>Donald R. Gorham, Ph.D.</i>	52
The Problem of In-Patient Psychotherapy; by <i>H. L. Freeman, M.A., B.M., B.Ch., D.P.M.</i>	60
The Effects of Meprobamate on Time Perception; by <i>C. G. Costello</i>	67
Psychodynamic and Psychotherapeutic Problems in Connection with Imipramine (Tofranil) Intake; by <i>H. Azima, M.D.</i>	74
Clinical Studies of a New Barbiturate (Nealbarbitone); by <i>A. A. Robin, M.D., D.P.M., D. P. Cronin, L.R.C.P.I., L.R.C.S.I., D.P.M., and L. Scotton</i>	83
A Double-Blind Trial to Investigate the Effects of Thorazine (Largactil, Chlorpromazine), Compazine (Stemetil, Prochlorperazine) and Stelazine (Trifluoperazine) in Paranoid Schizophrenia; by <i>Ian C. Wilson, M.B., Ch.B., D.P.H., D.P.M., James McKay, M.B., Ch.B., and Myron G. Sandifer, Jr., M.D.</i>	90
Possible Synergistic Effects of the New Thymoleptics in Connection with Poisoning; by <i>E. Howarth, M.B., Ch.B., D.P.M.</i>	100
Single Daily Dose Treatment of Psychiatric Patients with Phenothiazine Derivatives; by <i>F. J. Roberts, M.B., B.S.</i>	104
Oral Sernyl in Obsessive States; by <i>Brian M. Davies, M.D., M.R.C.P., D.P.M., D.C.H.</i>	109
A Monoamine Oxidase Inhibitor (Niamid) in the Treatment of the Mentally Subnormal; by <i>T. S. Davies, M.R.C.S., L.R.C.P., D.P.M.</i>	115
A Psychiatric Study Tour of the U.S.S.R.; by <i>Joseph Wortis, M.D.</i>	119
Management of Schizophrenia in Sarawak Mental Hospital, 1959; by <i>K. E. Schmidt, M.D., M.R.C.S., L.R.C.P., D.P.M.</i>	157
Epilepsy and Behaviour Disorder in Schoolchildren; by <i>Leslie E. Keating, M.A.(Cantab.)</i>	161
Treatment of Psychopaths; by <i>T. C. N. Gibbens, M.B.E., M.A., M.D., M.R.C.S., L.R.C.P., D.P.M.</i>	181

Supplement